Company intelligence / Profile preview
Avammune Therapeutics
Philadelphia, Pennsylvania, United Statesavammune.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Avammune has identified a first-in-class small molecule inhibitor of ADAR1 (AVA-ADR-001) which has demonstrated significant IFN response in vitro. The company is preparing for IND enabling studies and safety studies for their immuno-oncology assets.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
In discussions with major pharma and biotech companies for clinical translation
Beyond the preview
Go deeper on Avammune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avammune Therapeutics.